SEARCH

SEARCH BY CITATION

References

  • Abraham, J., Agrawal, M., Bakke, S., Rutt, A., Edgerly, M., Balis, F.M., Widemann, B., Davis, L., Damle, B., Sonnichsen, D., Lebwohl, D., Bates, S., Kotz, H. & Fojo, T. (2003) Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. Journal of Clinical Oncology, 21, 18661873.
  • Ajani, J.A., Safran, H., Bokemeyer, C., Shah, M.A., Lenz, H.J., Van Cutsem, E., Burris, H.A. III, , Lebwohl, D. & Mullaney, B. (2006) A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Investigational New Drugs, 24, 441446.
  • Belch, A., Kouroukis, T., Crump, M., Sehn, L., Gascoyne, R., Klasa, R., Jean, P. & Eisenhaue, E. (2004) Phase II trial of bortezomib in mantle cell lymphoma. Blood, 104, Abstract 608.
  • Bollag, D.M., McQueney, P.A., Zhu, J., Hensens, O., Koupal, L., Liesch, J., Goetz, M., Lazarides, E. & Woods, C.M. (1995) Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Research, 55, 23252333.
  • Chabner, B.A., Bates, S.E., Fojo, A.T., Spolyar, M. & Wilson, W.H. (1994) Drug resistance in adult lymphomas. Seminars in Hematology, 31, 7087.
  • Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O’Brien, S. & Rai, K.R. (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 87, 49904997.
  • Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244.
  • Chou, T.C., Zhang, X.G., Balog, A., Su, D.S., Meng, D., Savin, K., Bertino, J.R. & Danishefsky, S.J. (1998a) Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proceedings of the National Academy of Sciences of the United States of America, 95, 96429647.
  • Chou, T.C., Zhang, X.G., Harris, C.R., Kuduk, S.D., Balog, A., Savin, K.A., Bertino, J.R. & Danishefsky, S.J. (1998b) Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proceedings of the National Academy of Sciences of the United States of America, 95, 1579815802.
  • Chou, T.C., O’Connor, O.A., Tong, W.P., Guan, Y., Zhang, Z.G., Stachel, S.J., Lee, C. & Danishefsky, S.J. (2001) The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice. Proceedings of the National Academy of Sciences of the United States of America, 98, 81138118.
  • Fisher, R.I., Bernstein, S.H., Kahl, B.S., Djulbegovic, B., Robertson, M.J., De Vos, S., Epner, E., Krishnan, A., Leonard, J.P., Lonial, S., Stadtmauer, E.A., O’Connor, O.A., Shi, H., Boral, A.L. & Goy, A. (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. Journal of Clinical Oncology, 24, 48674874.
  • Gadgeel, S.M., Wozniak, A., Boinpally, R.R., Wiegand, R., Heilbrun, L.K., Jain, V., Parchment, R., Colevas, D., Cohen, M.B. & LoRusso, P.M. (2005) Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. Clinical Cancer Research, 11, 62336239.
  • Gerth, K., Bedorf, N., Hofle, G., Irschik, H. & Reichenbach, H. (1996) Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. The Journal of Antibiotics, 49, 560563.
  • Goy, A., Younes, A., McLaughlin, P., Pro, B., Romaguera, J.E., Hagemeister, F., Fayad, L., Dang, N.H., Samaniego, F., Wang, M., Broglio, K., Samuels, B., Gilles, F., Sarris, A.H., Hart, S., Trehu, E., Schenkein, D., Cabanillas, F. & Rodriguez, A.M. (2005) Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin’s lymphoma. Journal of Clinical Oncology, 23, 667675.
  • Holfe, G. (1996) Epothilones A and B novel 16-membered macrolides with cytotoxic activity: isolation, crystal structure, and confirmation in solution. Angewandte Chemie (International ed. in English), 35, 15671569.
  • De Jonge, M. & Verweij, J. (2005) The epothilone dilemma. Journal of Clinical Oncology, 23, 90489050.
  • Kowalski, R.J., Giannakakou, P. & Hamel, E. (1997) Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). Journal of Biological Chemistry, 272, 25342541.
  • Larkin, J.M. & Kaye, S.B. (2006) Epothilones in the treatment of cancer. Expert Opinion on Investigational Drugs, 15, 691702.
  • Lee, J.J. & Swain, S.M. (2006) Peripheral neuropathy induced by microtubule-stabilizing agents. Journal of Clinical Oncology, 24, 16331642.
  • Low, J.A., Wedam, S.B., Lee, J.J., Berman, A.W., Brufsky, A., Yang, S.X., Poruchynsky, M.S., Steinberg, S.M., Mannan, N., Fojo, T. & Swain, S.M. (2005) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. Journal of Clinical Oncology, 23, 27262734.
  • Mani, S., McDaid, H., Hamilton, A., Hochster, H., Cohen, M.B., Khabelle, D., Griffin, T., Lebwohl, D.E., Liebes, L., Muggia, F. & Horwitz, S.B. (2004) Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clinical Cancer Research, 10, 12891298.
  • Meng, D.S., Balog, A., Bertinato, P., Sorensen, E.J., Danishefsky, S.J., Zheng, Y.-H., Chou, T.-C., He, L. & Horwitz, S.B. (1997) Remote effects in macrolide formation through ring-forming olefin metathesis: an application to the synthesis of fully active epothilone congeners. Journal of the American Chemical Society, 119, 27332734.
  • Miller, T.P., Grogan, T.M., Dalton, W.S., Spier, C.M., Scheper, R.J. & Salmon, S.E. (1991) P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. Journal of Clinical Oncology, 9, 1724.
  • O’Connor, O.A. (2006) Pralatrexate: an emerging new agent with activity in T-cell lymphomas. Current Opinion in Oncology, 18, 591597.
  • O’Connor, O.A., Wright, J., Moskowitz, C., Muzzy, J., MacGregor-Cortelli, B., Stubblefield, M., Straus, D., Portlock, C., Hamlin, P., Choi, E., Dumetrescu, O., Esseltine, D., Trehu, E., Adams, J., Schenkein, D. & Zelenetz, A.D. (2005a) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. Journal of Clinical Oncology, 23, 676684.
  • O’Connor, O.A., Wright, J., Moskowitz, C., Straus, D., Portlock, C., Hamlin, P., Neylon, E., Evans, A., Winter, J., Gordon, L., Koc, O., Horvath, N., Blumel, S., Vose, J., Schenkein, D. & Zelenetz, A. (2005b) Targeting the proteasome pathway with bortezomib in patients with mantle cell (MCL) and follicular lymphoma (FL) produces prolonged progression free survival amnog responding patients: results of a multicenter phase II experience. Annals of Oncology, 16, Abstract 99.
  • Rose, W.C. (1992) Taxol: a review of its preclinical in vivo antitumor activity. Anti-Cancer Drugs, 3, 311321.
  • Rowinsky, E.K. & Calvo, E. (2006) Novel agents that target tublin and related elements. Seminars in Oncology, 33, 421435.
  • Rowinsky, E.K., Eisenhauer, E.A., Chaudhry, V., Arbuck, S.G. & Donehower, R.C. (1993) Clinical toxicities encountered with paclitaxel (Taxol). Seminars in Oncology, 20, 115.
  • Sarris, A.H., Hagemeister, F., Romaguera, J., Rodriguez, M.A., McLaughlin, P., Tsimberidou, A.M., Medeiros, L.J., Samuels, B., Pate, O., Oholendt, M., Kantarjian, H., Burge, C. & Cabanillas, F. (2000) Liposomal vincristine in relapsed non-Hodgkin’s lymphomas: early results of an ongoing phase II trial. Annals of Oncology, 11, 6972.
  • Smith, S.M., Pro, B., Van Besien, K., Conner, K., Karrison, T., Wong, S., Stiff, P. & Vokes, E. (2005) A phase II study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin’s lymphomas. Journal of Clinical Oncology, 23, Abstract ???.
  • Strauss, S.J., Maharaj, L., Hoare, S., Johnson, P.W., Radford, J.A., Vinnecombe, S., Millard, L., Rohatiner, A., Boral, A., Trehu, E., Schenkein, D., Balkwill, F., Joel, S.P. & Lister, T.A. (2006) Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. Journal of Clinical Oncology, 24, 21052112.
  • Su, D.S. (1997) Total synthesis of (-) epothilone: an extension of the Suzuki coupling method and insigfhte into structure activity relationships of the epithlones. Angewandte Chemie (International ed. in English), 36, 757759.
  • Thomas, E., Tabernero, J., Fornier, M., Conte, P., Fumoleau, P., Lluch, A., Vahdat, L., Bunnell, C.A., Burris, H.A., Viens, P., Baselga, J., Rivera, E., Guarneri, V., Poulart, V., Klimovsky, J., Lebwohl, D. & Martin, M. (2007) Phase II clinical trial of Ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane resistant metastatic breast cancer. Journal of Clinical Oncology, 23, 33993406.
  • Wilson, W.H., Bryant, G., Bates, S., Fojo, A., Wittes, R.E., Steinberg, S.M., Kohler, D.R., Jaffe, E.S., Herdt, J. & Cheson, B.D. (1993) EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin’s lymphoma. Journal of Clinical Oncology, 11, 15731582.
  • Zhuang, S.H., Agrawal, M., Edgerly, M., Bakke, S., Kotz, H., Thambi, P., Rutt, A., Balis, F.M., Bates, S. & Fojo, T. (2005) A phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer, 103, 19321938.